Everbliss 5 mg contains Everolimus, a targeted therapy belonging to the class of mTOR inhibitors.
It is used to treat various advanced cancers and certain non-cancerous tumours by interfering with specific cell growth pathways.
Available as a convenient oral tablet, Everbliss allows patients to continue their cancer treatment or tumour management at home, under close monitoring by their healthcare team.

Mechanism of Action

Everolimus specifically targets the mammalian target of rapamycin (mTOR), a key protein that controls cell growth, proliferation, metabolism, and the formation of new blood vessels (angiogenesis).

• By inhibiting the mTORC1 pathway, Everolimus slows down or stops abnormal cell division and reduces the blood supply to tumours.

• It also helps regulate immune responses, which is why it’s sometimes used in transplant medicine (to prevent organ rejection), although Everbliss is primarily formulated for oncology.

  Uses / Indications

  Everbliss is indicated in the treatment of several conditions, including:

  • Advanced hormone receptor-positive, HER2-negative breast cancer (often in combination with exemestane) after failure of other treatments.

  • Advanced renal cell carcinoma (kidney cancer), typically after progression on VEGF-targeted therapies.

  • Neuroendocrine tumours (NETs) of the pancreas, lung, or gastrointestinal tract that are non-functional but progressive.

  • Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC), when surgery isn’t an option.

  • Renal angiomyolipoma associated with TSC.

    Adverse Effects

    Everolimus can cause side effects due to its impact on cell growth and immune pathways.

    Common side effects include:

    • Mouth ulcers (stomatitis): very common and often requiring supportive mouthwashes.

    • Fatigue, loss of appetite.

    • Mild diarrhoea or nausea.

    • Skin rash or acne-like eruptions.

    • Mild increase in cholesterol or blood sugar levels.